Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study

• by Elizabeth K. O’Donnell, Omar Nadeem, Jacob P. Laubach, Giada Bianchi, Andrew R. Branagan, Brea C. Lipe, Paul G. Richardson, Ehsan Malek, Robb S. Friedman, Ajay K. Nooka, Robert Redd, Noopur S. Raje, Andrew J. Yee

• November 2, 2026

Why Roswell Park for Hepatobiliary Cancer

Roswell Park Comprehensive Cancer Center performs more than 100 surgeries for patients with liver and pancreatic cancers every year, making it a high-volume center specializing in these rare diseases.

• October 27, 2026

• 2 min

Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

• by Adam D. Cohen, Joshua Richter, Suzanne Trudel, Alexander Lesokhin, Jacob P. Laubach, Sheeba K. Thomas, Simon J. Harrison, Luciano J. Costa, Andrew Spencer, Rafael Fonseca, Peter A. Forsberg, Jesus G. Berdeja, Rayan Kaedbey, Nizar J. Bahlis, Paula Rodriguez-Otero, Maria-Victoria Mateos, Tulika Tyagi, Divya Samineni, Wenyu Liu, Rin Nakamura, Voleak Choeurng, Chihunt Wong, James Cooper, Amrita Krishnan

• October 20, 2026

Survival outcomes with Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics

• by Mike Wenzel, Quynh Chi Le, Carolin Siech, Benedikt Hoeh, Konrad Klimek, Christian Happel, Fred Saad, Felix Preisser, Derya Tilki, Markus Graefen, Thomas Steuber, Tobias Maurer, Maximilian C. Kriegmair, Pierre I. Karakiewicz, Felix K. H. Chun, Daniel Groener, Philipp Mandel

• October 20, 2026